NOLA.com6d
Chronic lung disease rates increase in Louisiana, despite national rates remaining the same
In 2021,138,825 people died from COPD in the U.S., making it the sixth overall leading cause of death and the fifth ...
News Medical on MSN8h
Addressing COPD and metabolic syndrome requires comprehensive research efforts
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
manilatimes1d
Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease
Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...
News Medical on MSN16h
Smoking before age 15 significantly increases risk of chronic lung disease
A study reveals childhood smoking significantly increases COPD risk in adulthood, highlighting the need for targeted ...
Expanded research on COPD and metabolic syndrome would advance patient-centered care, expert argues
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
Low birth weight may increase risk for later COPD
Individuals in the lowest quintile of birth weight appear to have an increased risk for subsequent chronic obstructive ...
California wildfires: How smoke, poor air quality can impact health of people hundreds of miles from Los Angeles
Smoke from wildfires — like the ones in Los Angeles — can have health consequences. Here's what experts expect.
Childhood smoking increases a person’s risk of developing COPD
Childhood smoking before age 15 increases a person’s risk of developing chronic obstructive pulmonary disease (COPD), according to a new study.
Verywell Health on MSN8h
Inhaling Wildfire Smoke Can Cause Long-Term Health Risks: How To Limit Your Exposure
While wildfires can cause immediate destruction to homes and towns, a few weeks of smoke exposure should not have long-term ...
Pharmaceutical Technology10d
TRN-157 by Theron Pharmaceuticals for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
TRN-157 is under clinical development by Theron Pharmaceuticals and currently in Phase I for Chronic Obstructive Pulmonary Disease (COPD).
Pharmaceutical Technology10d
AZD-6793 by AstraZeneca for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
AZD-6793 is under clinical development by AstraZeneca and currently in Phase I for Chronic Obstructive Pulmonary Disease (COPD).